S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:ASLN

ASLAN Pharmaceuticals (ASLN) Price Target & Analyst Ratings

$3.91
-0.03 (-0.76%)
(As of 05/26/2023 03:59 PM ET)
Compare
Today's Range
$3.80
▼
$4.00
50-Day Range
$2.62
▼
$4.59
52-Week Range
$1.70
▼
$4.95
Volume
8,400 shs
Average Volume
45,280 shs
Market Capitalization
$54.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

ASLAN Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$16.00
309.21% Upside
High Prediction$17.00
Average Prediction$16.00
Low Prediction$15.00
TypeCurrent
5/29/22 to 5/29/23		1 Month Ago
4/29/22 to 4/29/23		3 Months Ago
2/28/22 to 2/28/23		1 Year Ago
5/29/21 to 5/29/22
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$16.00$16.00$18.75$31.67
Predicted Upside309.21% Upside315.21% Upside349.83% Upside368.67% Upside
Get ASLAN Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.


ASLN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ASLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ASLAN Pharmaceuticals Stock vs. The Competition

TypeASLAN PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside309.21% Upside1,136.42% Upside196.43% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/28/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$20.00 ➝ $17.00+300.00%
2/27/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight$20.00 ➝ $15.00+261.27%
(Data available from 5/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ASLN Price Target - Frequently Asked Questions

What is ASLAN Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for ASLAN Pharmaceuticals stock is Buy based on the current 2 buy ratings for ASLN. The average twelve-month price prediction for ASLAN Pharmaceuticals is $16.00 with a high price target of $17.00 and a low price target of $15.00. Learn more on ASLN's analyst rating history.

Do Wall Street analysts like ASLAN Pharmaceuticals more than its competitors?

Analysts like ASLAN Pharmaceuticals more than other Medical companies. The consensus rating score for ASLAN Pharmaceuticals is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how ASLN compares to other companies.

Does ASLAN Pharmaceuticals's stock price have much upside?

According to analysts, ASLAN Pharmaceuticals's stock has a predicted upside of 315.21% based on their 12-month price targets.

What analysts cover ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals has been rated by HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ASLN) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -